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Summary
A major aim of evidence-based medicine is to assist
clinical decision-making by providing the most
current and reliable medical information. Systematic
reviews and meta-analyses are important tools in
this process. Systematic reviews identify and com-
pile relevant evidence, while meta-analyses sum-
marize and quantify the results of such reviews.
Results from meta-analyses are, at present, the
main source of summary evidence for the efficacy
of treatments for a specific condition. They are
important tools for helping to choose among
treatment options, although they cannot be used
to directly compare the magnitude of the effect of
various therapies. However, the methods used and
the consequent clinical value of the results, may be
poorly understood by clinicians, who may therefore
not take full advantage of the evidence.
Recently, a panel of experts in osteoporosis and
evidence-based medicine applied rigorous, vali-
dated, scientific standards to produce a systematic
review and meta-analysis of randomized controlled
trials of anti-resorptive agents used to treat osteo-
porosis. They found that, although several agents
reduced the risk of vertebral fracture, only two,
alendronate and risedronate, demonstrated convinc-
ing evidence for both non-vertebral and vertebral
fracture risk reductions. The clinical implication of
these results is that there are important differences in
anti-fracture efficacy among currently available
agents. In the absence of evidence from head-to-
head clinical trials and because of the systematic
nature and methodological rigor of the analyses,
these data provide important information for clinical
decision-making.
Introduction
In recent years, emphasis on ‘evidence-based’
clinical decision making has increased, but
some confusion about the principles and their
use remains. The practice of evidence-based
medicine involves the application, in the man-
agement of individual patients, of the best avail-
able scientific information. Large, well-conducted
clinical trials or meta-analyses of these trials
are considered to provide the best quality
evidence. Systematic reviews performed accord-
ing to standard guidelines provide quantitative,
objective summaries of the available evidence
and thereby provide important information to
the clinician.1
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Osteoporosis is widely prevalent in the older
population, and frequently results in fragility
fractures, which are associated with morbidity,
mortality, considerable health care costs, and
diminished quality of life.2,3 Both men and women
experience bone loss with age that can lead to
osteoporosis, but postmenopausal women are
particularly at risk because of the substantial decline
in bone mass and changes in bone architecture
that are associated with oestrogen deficiency. In
the past decade, well-designed clinical trials have
shown that several treatments decrease fracture
risk in postmenopausal women with low bone
mass, and clinicians now must evaluate the relative
merits of these options in order to make informed
decisions about therapy.
Recently, a team of experts in evidence-based
medicine methodology and osteoporosis research
(The Osteoporosis Methodology Group, OMG,
and The Osteoporosis Research Advisory Group,
ORAG) conducted a series of systematic reviews
and meta-analyses of antiresorptive osteoporosis
therapies.4–12 The OMG/ORAG meta-analyses
collectively represent a comprehensive summary
of the efficacy of treatments for osteoporosis. The
objectives of the current article are to describe why
systematic reviews and meta-analyses provide
the highest level of evidence, and use this infor-
mation to illustrate its application to the current
treatments for osteoporosis.
Hierarchy of clinical evidence
Scientific evidence varies in strength and reliability,
and can be represented as a hierarchy of relative
quality, as presented in Figure 1.13 This hierarchy
is arranged according to sound statistical principles,
and evidence used in decision-making should
come from as high in the hierarchy as possible.
Large, well-conducted randomized controlled
trials (RCTs) and meta-analyses of results of multiple
large RCTs occupy the top of the hierarchy and,
ideally, medical decisions should be based on the
results of such studies. In contrast, personal experi-
ence, even that of experts or respected authorities,
provides the poorest quality evidence, because it
is the most subjective and prone to bias. Although
RCTs have certain limitations, they are considered
to provide the best evidence of the effectiveness of
a particular therapy. Randomization helps ensure
that patients in the active treatment and control
groups have similar characteristics at baseline, while
blinded evaluation of outcome measures according
to uniform criteria reduces the chance of bias in
the analysis and interpretation of the trial results.
As a consequence, differences observed between
treatment and control groups can be attributed
confidently to the effect of the treatment rather
than to other factors such as the characteristics
of the participants or to incidental confounders,
which should be equally distributed among
groups.14
Even among RCTs, the strength of reported
evidence can vary. Large trials are more able to
identify treatment effects than smaller trials, and
provide more precise estimates of the magnitude
of any such effect. Smaller RCTs are more com-
monly available, but the results may be conflicting
or inconclusive because the statistical power may
be inadequate to permit precise estimates of effect.
The strongest evidence derived from a single study
comes from analyses of primary and secondary
outcomes that were specified before the study
began. ‘Post hoc’ and subgroup analyses have less
value, because the chance of identifying spurious
differences (coincidences) becomes greater when
multiple analyses are performed, and because
randomization was not based on such subgroups.15
Observational studies, including case reports, case
series, cross-sectional surveys, case-control studies,
and prospective cohort studies are subject to a
variety of possible biases. Fundamentally, the
bias reflects the fact that study groups are not
similar in all respects except for the treatment.16,17
Meta-analysis combines results from multiple
trials, some of which may have had limited ability
to demonstrate a treatment effect because of their
small size. It increases the effective size of the
study population and thereby the power to detect
and quantify a treatment effect.
Systematic review and
meta-analyses of osteoporosis
therapies
Inclusion criteria and assessment of
methodological quality
The OMG/ORAG investigators defined, and
strictly adhered to, detailed pre-specified methods
for the systematic review, to help ensure that the
reviews would be comprehensive with reduced
chance of bias. Only RCTs, the highest level of
evidence, were included and the methodological
quality of each trial was determined using formal
objective criteria. Studies were included in the
review only if deemed eligible by multiple inde-
pendent reviewers, and four aspects of trial design
and conduct that affect validity were evaluated
for each.
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(i) Concealment of randomization
Individuals responsible for determining eligibility
should not know which treatment participants will
be receiving if they enter the trial. Trials that
inadequately conceal patient allocation tend to
overestimate treatment effects.18
(ii) Blinding to treatment
Trials are more likely to yield unbiased results
if participants and investigators, including those
who assess outcomes, are unaware of treatment
allocation.19
(iii) Completeness of follow-up
Trials with large losses to follow-up (defined as
420% for these meta-analyses) are at risk of losing
the balance of baseline characteristics initially
achieved by randomization. Although the investi-
gators did not explain their choice of threshold,
losses 420% are typically considered to jeopardize
the validity of trial results.20 If participants with
fractures preferentially drop out of the placebo
group in osteoporosis trials, the observed results
may underestimate the treatment effect, whereas
the converse will be the case if fracture drop-
outs are concentrated in the treatment group. The
effects of this imbalance cannot be calculated
or corrected for by any statistical method, and
results from such studies must be interpreted with
great caution.21
(iv) Analysis according to
intention-to-treat (ITT)
The ITT principle requires that all participants
be analysed in the group to which they were
randomized, irrespective of whether they received
the intended treatment or completed the trial.
Although this may be counter-intuitive, it is a
conservative approach because it tends to under-
estimate the treatment effect. Failure to use ITT
(for example, including only participants who
took all study medication in the primary analysis)
can introduce bias, because it can destroy the
original randomization by selecting subgroups, and
lead to imbalance in baseline characteristics.21,22
Scrupulous attention to methodology is essential
to ensure the validity of a meta-analysis. RCTs of
osteoporosis treatment often use multiple doses of
drugs and different durations of treatment. Pooling
of studies simplifies the systematic review and
increases the statistical power of the meta-analysis,
but is considered appropriate only if the same
magnitude of effect can be demonstrated across
a range of patients, interventions, and outcomes.
This is evaluated statistically as heterogeneity, by
comparing a model that includes a variable for
dose or year of treatment with a corresponding
model that does not consider dose or duration.
According to the OMG/ORAG protocol, study
results were pooled only when these two models
did not differ significantly, so that heterogeneity
was absent.
Systematic Review of Several Large RCTs
Single Large RCT
Systematic Review of Several Small RCTs
Single Small RCT
Systematic Review of Several Cohort Studies
Single Cohort Study
Systematic Review of Several Case-Control Studies
Single Case-Control Study
Systematic Review of Several Cross-Sectional Studies
Single Cross-Sectional Study
Case Series
Figure 1. Hierarchy of clinical evidence.
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In order to examine any observed heterogeneity
in greater detail, the OMG/ORAG investigators
pre-defined factors that might be related to this
effect, including differences in (i) prevention vs.
treatment populations, (ii) prevalent vertebral frac-
ture(s), (iii) losses to follow-up during the study,
(iv) levels of calcium intake during trials, and
(v) concomitant use of vitamin D supplements. For
example, the ORAG/OMG investigators hypothe-
sized that treatment effects could differ in women
with moderately low bone density (prevention
studies) and women with established osteoporosis
(treatment studies). They therefore differentiated
prevention from treatment trials using a predefined
set of criteria, including BMD, history of previous
fracture and age (Table 1). Statistically signifi-
cant heterogeneity was defined as p4 0.10. If the
heterogeneity p value for any factor was lower than
0.10, chance alone was considered to be an
unlikely explanation for the difference, and that
factor was considered responsible for the hetero-
geneity. If heterogeneity was encountered, those
groups were reported separately, because pooling
of results was not considered statistically sound.
For example, if prior fracture was associated with
heterogeneity of treatment effect, then groups with
and without such a history would be reported
separately. In the case of alendronate, as will be
explained in greater detail in the results, such
heterogeneity was identified when evaluating the
effects of doses510mg (vs. doses510mg) on non-
vertebral fracture incidence; these doses were thus
reported separately.
Two general mathematical models with differing
underlying principles are used in meta-analysis:
fixed effects and random effects.23 Functionally,
the random effects model usually produces wider
confidence intervals, and is considered to be the
more conservative option. In the fixed-effects
model, the studies included are considered to
comprise the entire universe of information from
which the most precise estimate is to be derived.
Variability, therefore, derives mostly from study size,
and larger studies are weighted more heavily.
In contrast, the random effects model assumes
that the results included represent only a random
sample of the possible estimates of treatment
effect. In this model, variability includes both
within and between study components, resulting
in wider confidence intervals. The OMG/ORAG
investigators chose to use the more conservative
random effects model; thus, statistically significant
treatment effects were relatively more difficult
to demonstrate than if a fixed-effects model had
been used.
Outcomes
BMD, vertebral fracture, and non-vertebral fracture
were the outcomes of interest in the OMG/ORAG
meta-analyses, and separate analyses were con-
ducted for each of these outcomes for each of
the agents. Fracture analyses were based on the
proportion of patients with new fractures rather
than the number of new fractures, because analys-
ing the number of fractures overestimates the
treatment effect unless special statistical techniques
are used (which was not possible in these meta-
analyses). This is of particular importance for
osteoporosis, since the occurrence of a fracture
represents a major risk for experiencing a sub-
sequent fracture.24 Adverse event profiles and
discontinuation rates were also evaluated when
available.
Studies with positive results may be more likely
to be published than studies with negative results,
and this can overestimate the actual treatment
effect when data are combined. Moreover, trial
results may be published more than once, which
may also compromise the validity of a systematic
review. To identify and limit this effect (known
as publication bias) as much as possible, data
Table 1 Criteria used by OMG/ORAG to distinguish osteoporosis prevention and treatment studies
Criterion Prevention Treatment
Population Postmenopausal women Postmenopausal women
Study classification Primary prevention Secondary prevention
T-scorea Within 2 SD of mean peak bone mass At least 2 SD below peak bone mass
Prevalence of vertebral
fracture at baselineb
420% of population >20% of population
Mean agec 462 years >62 years
aBecause of controversy about a threshold of 2 SD, analyses for alendronate and risedronate were repeated using a
threshold of 2.5 SD below young adult normal. bThis criterion applied if no BMD results were provided. cThis criterion
applied if neither BMD results nor vertebral fracture prevalence was provided.
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from unpublished studies are included in the
meta-analyses, duplicate publications are identified
and omitted, and statistical tests are performed to
detect such bias. A funnel plot, of study sample size
or precision (which depends on sample size) on
the horizontal axis and treatment effect size on the
vertical axis, is generally used in this process.23
If publication bias exists, such that null or
unfavourable results are not published, the lower
left corner of the plot, which should show
small studies with null or negative results, will be
empty.
Meta-analysis results
Methodological rigor
The literature review process identified eight
antiresorptive agents for treating postmenopausal
osteoporosis, for which systematic reviews could
be performed: alendronate, calcitonin, calcium,
etidronate, hormone replacement therapy (because
results of the Women’s Health Initiative had not
been published at the time of the review, they
were not included in this meta-analysis), raloxifene,
risedronate, and vitamin D (including pharmaco-
logical doses and nutritional supplements). The
reviewers found that studies of alendronate and
raloxifene best fulfilled the four predefined criteria
for study validity (concealment of allocation, blind-
ing, completeness of follow-up, and intention-to-
treat analysis), thus allowing greater confidence
in results of these studies. (Table 2) Studies of
etidronate, risedronate, and calcitonin were con-
sidered to be compromised by relatively large
losses to follow-up, and studies of calcitonin and
calcium generally failed to use intention-to-treat
analysis, so that less confidence could be placed
in these results. In addition, calcitonin trials
frequently failed to conceal treatment allocation,
and reported effects on BMD were larger in
calcitonin trials with inadequate concealment,
supporting the inference that this biased the study
results.
Vertebral fracture
Statistically significant reductions in the risk of
vertebral fracture, which ranged from 36% to 48%,
were found in the meta-analyses for alendronate,
risedronate, etidronate, raloxifene, and vitamin D
(Table 3). Treatment effects for alendronate,
risedronate, etidronate, and hormone replacement
therapy were very consistent across studies (homo-
geneity of effect), regardless of dose or duration.
Non-vertebral fracture
Only alendronate and risedronate significantly
reduced the risk of non-vertebral fracture (Table 3).
Alendronate, in doses 510mg, decreased the
risk of non-vertebral fractures by 49% (95%CI
31–62%), and there were sufficient data to conclude
that the risk reduction was similar at all non-
vertebral sites, including the hip. Moreover, these
risk reductions were similar for fracture sites that
had not previously been considered to be related
to osteoporosis. Alendronate demonstrated hetero-
geneity for non-vertebral fracture incidence, such
that doses 510mg had a significantly lesser
effect (13% reduction; 95%CI 2% increase, 27%
reduction). As a consequence, these results could
not be pooled, and were reported separately.
Furthermore, in one large trial of alendronate
Table 2 Methodological quality of studies included in the meta-analyses
Intervention No. of
studies
Blinding Concealed
treatment
allocation
ITT analysis Loss to follow-up
55% 5–20% 420%
Alendronate 11 11 11 10 2 6 3
Risedronate 8 8 6 8 – 1 7
Hormone therapy 57 31 5 Incomplete Incomplete data
Vitamin D 25 18 10 9 – 8 13
Calcitonin 30 16 15 4 6 13 9
Raloxifene (pooled) 7 7 7 7 – 3 3
Etidronate (400mg, vertebral) 13 6 9 12 1 5 7
Calcium 15 13 13 1 – 13 2
From Cranney A, et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;
23:570–8. Reproduced with permission of The Endocrine Society, Copyright 2002.
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(Fracture Intervention Trial), 5mg was given for
2 years followed by 10mg for the remainder of
the study,25 and heterogeneity of dose effect
rendered this study ineligible for inclusion in the
meta-analysis of non-vertebral fracture.
Risedronate (2.5 and 5mg doses combined,
because they exhibited homogeneity of effect)
was the only other antiresorptive agent to show a
significant reduction in non-vertebral fracture risk
(27%, 95%CI 13–39%), but data were insufficient
to comment on site-specific effects, although
hip fracture risk reduction was shown in a single
trial.26 Neither calcium nor hormone replacement
therapy significantly reduced either vertebral or
non-vertebral fracture risk.
Bone mineral density (BMD)
The biggest gains in lumbar spine BMD, ranging
from 4.5% to 7.5%, were seen with alendronate,
risedronate, and hormone therapy (Figure 2).
More modest BMD increases, in the range of 2.4%
to 4.1%, were seen with calcitonin, etidronate,
and raloxifene. Neither calcium nor vitamin D had
a significant effect on spine BMD. The relative
increases in BMD for these eight agents were
similar at the hip. In general, the magnitude of
effect on BMD correlated with non-vertebral
fracture risk reduction, so that the agents that
produced the greatest increase in BMD (alendronate
and risedronate) demonstrated the greatest anti-
fracture efficacy, especially at non-vertebral sites.
The magnitude of vertebral fracture reduction
was less closely associated with BMD change:
alendronate, raloxifene, and risedronate all reduced
vertebral fracture incidence, despite differing
increases in BMD. Higher doses of alendronate,
hormone replacement therapy, and risedronate
were associated with greater increases in BMD,
but no such dose-response relationship was shown
for calcitonin or calcium. Longer duration of
treatment produced larger increases in BMD with
alendronate, hormone therapy, raloxifene, and
risedronate, but not with other agents. Tests for
heterogeneity did not detect differences in the
magnitude of effects on lumbar spine BMD between
prevention and treatment populations, nor were
significant differences identified based on years
Table 3 Magnitude of therapy effect on fracture risk reduction
Non-vertebral fractures Vertebral fractures
Intervention Relative risk
reduction (95%CI)
Trials
(patients)
Relative
risk
p Relative risk
reduction (95%CI)
Trials
(patients)
Relative
risk
p
Agents with statistically significant reductions in non-vertebral fracture,
with or without reduction in vertebral fractures
Alendronate 410mg/day
(non-vertebral)
49% (31–62%) 6 (3723) 0.51 50.01
Alendronate 45mg/day
(vertebral)
48% (35–56%) 8 (9360) 0.52 50.01
Risedronate 52.5mg/day
(non-vertebral)
27% (13–39%) 7 (12 958) 0.73 50.01
Risedronate 52.5mg/day
(vertebral)
36% (23–46%) 5 (2604) 0.64 0.01
Agents with statistically significant reductions in vertebral fracture only
Vitamin D 23% (4 to 43%) 6 (6187) 0.77y 0.09 37% (12–55%) 8 (1130) 0.63 50.01
Calcitonin 20% (9 to 41%) 1 (1245) 0.80 0.16 21% (0–38%) 1 (1108) 0.79 0.05
Raloxifene (pooled) 9% (6 to 21%) 2 (6961) 0.91 0.24 40% (30–50%) 1 (6828) 0.60 0.01
Etidronate
(400mg, vertebral)
1% (42 to 31%) 7 (867) 0.99 0.97 37% (8–56%) 9 (1076) 0.63 0.02
Agents without statistically significant reduction in fracture
Calcium 14% (72 to 57%) 2 (222) 0.86 0.66 23% (9 to 46%) 5 (576) 0.77 0.14
Hormone therapy 13% (8 to 29%) 6 (3986) 0.87 0.10 34% (7 to 59%) 5 (3117) 0.66 0.12
Agents are presented in order by magnitude of nonvertebral fracture risk reduction within each category. Only the two newer
bisphosphonates, alendronate and risedronate, significantly reduced both vertebral and non-vertebral fractures. ySignificant
heterogeneity between studies, based on p40.10. From Cranney A, et al. IX: Summary of meta-analyses of therapies
for postmenopausal osteoporosis. Endocr Rev 2002; 23:570–8. Reproduced with permission of The Endocrine Society,
Copyright 2002.
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of follow-up. This is shown in Figure 2, which
presents the mean percent change in BMD for each
of the agents, based on pooled data, generally using
data from the last year of a multi-year trial.
Discontinuation due to adverse events
Tolerability for all of the agents examined was good
and only vitamin D (RR 1.37, 95%CI 1.01–1.88)
and, barely, raloxifene (RR 1.15, 95%CI 1.00–1.33),
had discontinuation rates that were significantly
different from placebo (Table 4).
Discussion
Because meta-analysis pools data from as many
studies as possible, the estimates of treatment
effect are more precise than those available from
any individual trial. However, the validity of the
meta-analysis depends on the methodological
rigor with which it is conducted. In the OMG/
ORAG analyses, the proportion of participants
who incurred fractures in each group was used
to estimate the treatment effects, which provides
consistency and comparability among studies and
analyses. As a consequence, these estimates of
effect using proportional analysis may differ from
the results reported in the original publications in
which time-to-event, or survival, analysis was used.
This is especially relevant in the case of vertebral
fractures, where in the presence of relatively large
losses to follow-up (even if the losses are random),
time-to-event analysis results in a larger treatment
effect than does proportional analysis.27
Reducing the risk of non-vertebral fracture is
a critical objective of osteoporosis treatment,
because these fractures have important effects on
health and quality of life. There is at present
convincing evidence of non-vertebral fracture risk
reduction for only alendronate and risedronate.
Alendronate (410mg/day) reduced the risk of
non-vertebral fractures by 49% (95%CI 31–62%),
with consistent risk reductions at all fracture sites,
including those not traditionally considered to be
related to osteoporosis. Risedronate (42.5mg/day)
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Figure 2. Mean percent change in BMD at the lumbar spine for agents in OMG/ORAG meta-analyses. Magnitude of
increase in spine BMD after 1–5 years on treatment versus placebo. Longer treatment durations resulted in larger BMD effects
with alendronate, risedronate, raloxifene and HT. This was not the case for vitamin D, calcitonin, or calcium. Greater
increases in BMD were reported in agents that significantly reduced the risk of non-vertebral fractures. Black bars indicate
agents with confirmed non-vertebral and vertebral fracture risk reduction. Gray bars indicate agents with vertebral fracture
risk reduction only. White bar indicates agents without significant fracture risk reductions.
Table 4 Relative risks of discontinuing therapy for
adverse events
Intervention Relative risk (95%CI)
Alendronate 1.15 (0.93–1.42)
Risedronate 0.94 (0.80–1.10)
Hormone therapy NA
Vitamin D 1.37 (1.01–1.88)
Calcitonin Similar in treatment
and control groups
Etidronate 0.93 (0.70–1.23)
Raloxifene 1.15 (1.00–1.33)
Calcium NA
NA, not available.
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reduced the risk of non-vertebral fractures by 27%
(95%CI 13–39%), but because of power limitations,
the analysis could not conclude that this reduc-
tion pertained at individual fracture sites,6,12 except
for hip fractures in women 70–79 years of age with
low BMD.26
Reduction of vertebral fracture risk should
be another therapeutic goal, given the literature on
the impact of fractures on quality of life, morbidity
and mortality.2,28 Based on the methodological
quality, the magnitude of the treatment effect, the
narrowness of the confidence intervals and the
consistency of results among studies, evidence
of vertebral fracture risk reduction was strongest
for alendronate and risedronate, but raloxifene,
vitamin D, etidronate, and calcitonin also reduced
this risk.
The type of analysis performed in individual trials
may have important implications for reported
efficacy. In situations of considerable loss to
follow-up early in the trial, Kaplan-Meier or Cox
proportional hazards time-to-event analysis can
yield biased estimates of the true reduction in
vertebral fracture risk.27 Time-to-event analysis
censors individuals at the time they are lost to
follow-up or have the clinical event of interest, so
they are considered as part of the denominator
only up to this point. When numbers of drop-
outs are large, especially early in the study, the
estimates of cumulative incidence at these time
points carry a disproportionate weight in calculating
the final overall cumulative incidence, since the
Kaplan-Meier estimator weights early events more
heavily than later ones. This generally has little
effect on non-vertebral fracture outcomes. Further-
more, because time to event for each trial partici-
pant is not available to meta-analysts, neither
Kaplan-Meier nor Cox proportional hazards
methods can be used to derive summary estimates.
As noted by the ORAG/OMG authors, additional
research is necessary to demonstrate whether agents
that offer only vertebral fracture protection can
improve quality of life.12
The choice among treatment options is usually
determined by a combination of the clinician’s
perception of the quality of the clinical trial
evidence for a particular agent and the patient’s
personal priorities/preferences. In the case of osteo-
porosis, these considerations may include non-
skeletal factors such as wanted or un-wanted effects
on breast, urogenital tract or cardiovascular system.
As noted by the OMG/ORAG investigators, the
magnitude of the summary treatment effects of
two or more agents cannot be directly compared
to one another, because the estimates were derived
from different sets of populations that were not
randomized with respect to one another. As a
consequence, even if the confidence intervals
for two estimates do not overlap, a statistically
significant difference between these agents cannot
be inferred.
Head-to-head trials with fracture endpoints
would provide the most reliable and valid compar-
ison between the effectiveness of agents, but such
trials would be very large and expensive and are,
consequently, unlikely to be performed. For exam-
ple, in order to demonstrate equivalence between
two treatments that reduce fracture incidence
by 50% relative to placebo in a population with a
5% fracture rate, the sample size per group would
need to be 430 000.29 Several head-to-head
trials have been conducted to compare the relative
effects of antiresorptive therapies on BMD and
bone turnover,30–35 but none was designed to
assess effects on fracture incidence. However,
among antiresorptive agents, the magnitude of
the BMD increase is positively associated with
non-vertebral fracture reduction,36,37 although the
extent to which it may explain this effect is a
particularly contentious issue.38
Although the systematic review provides powerful
evidence as to the consistency of effect on BMD
and fracture risk reduction, it does not specifically
address issues of comparison between agents.
However, statistical techniques for indirectly com-
paring agents to a common comparator (such as
placebo) generally show agreement with results of
meta-analyses and head-to-head RCTs comparing
the same agents.39–41 In effect, by mathematically
combining placebo groups for the active agents,
strata are constructed that include participants
from each of the strata included in each of the
treatment groups. As a consequence, comparisons
between the agents can be mediated through this
combined placebo group. This procedure adds to
variability of estimates of treatment effects, so that
adjusted indirect comparisons tend to be more
conservative, with wider confidence intervals and
less likelihood of demonstrating statistical signifi-
cance.39 When these techniques were applied to
the OMG/ORAG results, alendronate had signifi-
cantly greater efficacy in preventing non-vertebral
fracture than any of the other agents.42
Systematic reviews and meta-analyses do have
limitations that largely depend on the methodo-
logical quality of the original studies. If the original
studies contain one or more biases, or if negative
studies are unpublished, the resultant meta-analysis
may be flawed. Analyses that neglect important
secondary outcomes and side-effects are incom-
plete.4 It must also be recognized that a systematic
review is helpful in making therapeutic decisions
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only if relevant patient populations and clinical
outcomes are evaluated.43 The OMG/ORAG sys-
tematic reviews focused on treatment effects in
postmenopausal women with known low bone
density, the population at highest risk of fracture,
so the findings are useful for the clinical manage-
ment of such patients.
Concurrent with the publication of these meta-
analyses, data from the Women’s Health Initiative
(WHI), a large randomized controlled trial evaluat-
ing the effects of oestrogen plus progestin (Prempro)
in post-menopausal women, were published.
The WHI investigators reported that this regimen
of hormone therapy reduced vertebral fractures
by 34% and non-vertebral fractures by 23%.44 The
magnitude of fracture risk reduction reported in
WHI was similar to the meta-analysis estimates,
and if WHI data are added to the OMG/ORAG
meta-analyses, hormone treatment significantly
reduced the risk of both vertebral (RR 0.70, 95%CI
0.52–0.94) and non-vertebral (RR 0.78, 95%CI
0.64–0.96) fractures. (Cranney, personal communi-
cation) Even more recently, results of the oestrogen-
only WHI trial have shown a similar reduction
in fracture incidence.45 However, because of the
risks associated with long-term use of hormone
therapy, it is no longer recommended solely for
prevention or treatment of osteoporosis.46,47
In summary, the results from the OMG/ORAG
meta-analyses provide a useful insight into the
strength of the evidence for effectiveness of different
osteoporosis therapies. Results from systematic
reviews and meta-analyses, considered together
with factors such as extra-skeletal benefits, risks,
cost, and patient preferences, can help clinicians
to identify the most effective agents for treating
postmenopausal osteoporosis.
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